Delcath (DCTH) Q4 2025 earnings review
Volume Growth Validated, But R&D Investments Reverse Bottom Line
Delcath successfully stabilized sequential revenue in Q4 after absorbing a mandatory 340B price cut in Q3. The company achieved massive full-year volume growth, driven by aggressive site activations for its HEPZATO therapy. However, the short-lived era of GAAP profitability has ended. Driven by a deliberate, massive scale-up in R&D expenses to fund Phase 2 trials in new indications, Q4 net income flipped back into negative territory. While the balance sheet is pristine ($91M cash, zero debt), investors must now underwrite a transition phase: flat near-term margin expansion traded for a significantly larger long-term total addressable market.
🐂 Bull Case
Delcath closed FY25 with $91M in cash and short-term investments and zero debt, generating $25.1M in Adjusted EBITDA for the year. They are fully self-funded to execute their pipeline expansion without diluting shareholders.
Data showing a 54.7% 1-year progression-free survival rate when combining HEPZATO with checkpoint inhibitors is a practice-changing catalyst that should dislodge hesitant prescribers.
🐻 Bear Case
After three consecutive quarters of positive net income, Q4 swung to a $1.9M loss as operating expenses outpaced flattened revenue growth.
Participation in the 340B drug pricing program permanently capped average revenue per kit starting in H2 2025, forcing the company to rely entirely on raw volume growth to drive top-line numbers.
⚖️ Verdict: ⚪
Neutral/Constructive. Management successfully launched HEPZATO and fortified the balance sheet. The reversion to net losses is a strategic choice to fund much larger total addressable markets (colorectal/breast cancer), but it means the stock will likely trade on clinical trial progress rather than near-term earnings beats.
Key Themes
Operating Leverage is Reversing
While gross margins remain exceptional (85%), operating expenses have completely swallowed the bottom line. R&D spending accelerated sequentially every quarter in FY25, peaking at $9.4M in Q4 (up 223% YoY), driven by new Phase 2 trials for mCRC and mBC. Consequently, Adjusted EBITDA is steadily decelerating from its Q2 peak.
CHOPIN Data and IO Synergy
The Phase 2 CHOPIN trial represents a massive technological and clinical driver. Combining CHEMOSAT with ipilimumab and nivolumab yielded a 54.7% 1-year progression-free survival rate compared to 15.8% for CHEMOSAT alone. This validates the thesis that treating liver metastases can 'make cold tumors hot' for immuno-oncology, overcoming primary physician reluctance to pause systemic therapies.
The 340B Pricing Squeeze (Macro Regulatory Impact)
To secure Medicaid/Medicare coverage—a necessary macro healthcare maneuver—Delcath entered the National Drug Rebate Agreement (NDRA). This mandates 340B pricing discounts, which wiped out 10-15% of the average revenue per kit starting in Q3. Q4 revenue of $20.7M confirms this lower revenue ceiling is permanent, shifting the burden entirely to site activations to generate growth.
Methodical Commercial Expansion
Site activation execution has been steady. The company ended FY25 with 28 active centers, up from 17 in Q1, and specifically highlighted 140% YoY procedure volume growth. Management plans to hit 40 active commercial centers by the end of FY26, which is heavily relied upon to hit the $100M revenue guidance floor.
Other KPIs
Stable. Gross margins remain excellent and highly consistent, matching the 86% achieved for the full year. This confirms manufacturing and supply chain costs are tightly controlled despite the WAC price compression from 340B discounts.
Accelerating. Up from $88.9M in Q3, despite funding the share buyback program. The company executed $6.0M in stock repurchases (628,572 shares) out of its $25M authorization. Maintaining a growing cash pile while buying back stock and funding massive clinical trials reflects stellar treasury management.
Guidance
Decelerating. A target of $100M implies ~17% YoY growth compared to the massive ~129% growth seen in FY25 (base effect). The guidance assumes a 20%+ increase in HEPZATO volume, indicating that actual kit pricing remains compressed and volume is the sole growth engine.
Stable. Perfectly in line with the 86% achieved in 2025, reassuring investors that supply chain economics remain intact.
Key Questions
R&D Spend Run-Rate
With R&D nearly tripling YoY in Q4 to $9.4M, what is the anticipated quarterly OpEx run-rate for 2026 as the mCRC and mBC trials ramp up?
Volume Elasticity from NDRA
You absorbed the 340B pricing hit in H2 2025 to remove financial barriers for hospitals. Have you seen concrete evidence of a volume uplift at eligible centers directly attributable to this improved hospital economic profile?
Capacity Constraints at Active Sites
With 28 active centers, are you seeing any capacity constraints (OR availability, staffing) limiting the 2 procedures/month average, and how are you directing referral networks to alleviate this?